Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc. on September 4, 2023. The Consideration shall be settled by the Company in the form of convertible bonds to be issued by the Company upon Completion. Transaction is subject formal agreement and approval of offer by acquirer board
Innovative Pharmaceutical Biotech Limited
Equities
399
BMG4783W1073
Industrial Machinery & Equipment
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.209 HKD | +2.45% | +0.48% | -4.57% |
May. 31 | Innovative Pharma Extends Long Stop Date for Convertible Bond Issuance | MT |
2023 | Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.57% | 45M | |
+10.40% | 44.18B | |
-0.37% | 36.23B | |
+10.31% | 7.22B | |
+18.20% | 6.98B | |
-15.86% | 4.69B | |
+21.55% | 1.47B | |
+9.01% | 1.46B | |
-0.89% | 1.45B | |
-3.56% | 981M |
- Stock Market
- Equities
- 399 Stock
- News Innovative Pharmaceutical Biotech Limited
- Innovative Pharmaceutical Biotech Limited entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.